APO Research
Talk to an analyst

APO RESEARCH · REPORT

Covid-19 Vaccine

A COVID-19 vaccine is a hypothetical vaccine against coronavirus disease 2019 (COVID-19). Although no vaccine has completed clinical trials, there are multiple attempts in progress to develop such a vaccine.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

A COVID-19 vaccine is a hypothetical vaccine against coronavirus disease 2019 (COVID-19). Although no vaccine has completed clinical trials, there are multiple attempts in progress to develop such a vaccine.

The genetic sequence of SARS-CoV-2, the coronavirus that causes COVID-19, was published on 11 January 2020, triggering intense global R&D activity to develop a vaccine against the disease. The scale of the humanitarian and economic impact of the COVID-19 pandemic is driving evaluation of next-generation vaccine technology platforms through novel paradigms to accelerate development, and the first COVID-19 vaccine candidate entered human clinical testing with unprecedented rapidity on 16 March 2020.

The global vaccine R&D effort in response to the COVID-19 pandemic is unprecedented in terms of scale and speed. Given the imperative for speed, there is an indication that vaccine could be available under emergency use or similar protocols by early 2021. This would represent a fundamental step change from the traditional vaccine development pathway, which takes on average over 10 years, even compared with the accelerated 5-year timescale for development of the first Ebola vaccine, and will necessitate novel vaccine development paradigms involving parallel and adaptive development phases, innovative regulatory processes and scaling manufacturing capacity.

Selected research

Market Analysis & Forecast

Global Covid-19 Vaccine Market Analysis and Forecast 2026-2032

28 December 2025199 pages

Choose your research edition.

Industry ResearchCovid-19 Vaccine Industry Research Report 2026112 pages · $2,950 USDIndustry Growth & TrendsGlobal Covid-19 Vaccine Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal Covid-19 Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Covid-19 Vaccine Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Covid-19 Vaccine Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

A COVID-19 vaccine is a hypothetical vaccine against coronavirus disease 2019 (COVID-19). Although no vaccine has completed clinical trials, there are multiple attempts in progress to develop such a vaccine.

The genetic sequence of SARS-CoV-2, the coronavirus that causes COVID-19, was published on 11 January 2020, triggering intense global R&D activity to develop a vaccine against the disease. The scale of the humanitarian and economic impact of the COVID-19 pandemic is driving evaluation of next-generation vaccine technology platforms through novel paradigms to accelerate development, and the first COVID-19 vaccine candidate entered human clinical testing with unprecedented rapidity on 16 March 2020.

The global vaccine R&D effort in response to the COVID-19 pandemic is unprecedented in terms of scale and speed. Given the imperative for speed, there is an indication that vaccine could be available under emergency use or similar protocols by early 2021. This would represent a fundamental step change from the traditional vaccine development pathway, which takes on average over 10 years, even compared with the accelerated 5-year timescale for development of the first Ebola vaccine, and will necessitate novel vaccine development paradigms involving parallel and adaptive development phases, innovative regulatory processes and scaling manufacturing capacity.

Read the full market overview

North America is the largest consumption place, with a consumption market share nearly 53.8% in 2026, Europe is the second largest consumption place with the consumption market share of 24.61% in 2026.

Report Includes

This report presents an overview of global market for Covid-19 Vaccine, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Covid-19 Vaccine, also provides the revenue of main regions and countries. Of the upcoming market potential for Covid-19 Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Covid-19 Vaccine revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Covid-19 Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Covid-19 Vaccine revenue, projected growth trends, production technology, application and end-user industry.

Covid-19 Vaccine Segment by Company

Moderna

CanSino Biologicals

Inovio Pharmaceuticals

Shenzhen Geno-Immune Medical Institute

GlaxoSmithKine

Pfizer

Johnson＆Johnson

Heat Biologics

Sanofi

Covid-19 Vaccine Segment by Type

DNA

Non-replicating Viral Vector

Protein Subunit

RNA

Others

Covid-19 Vaccine Segment by Application

Adults

Children

Covid-19 Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Covid-19 Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Covid-19 Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Covid-19 Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Covid-19 Vaccine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Covid-19 Vaccine company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Covid-19 Vaccine revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Covid-19 Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. DNA Major Player Table 3. Non-replicating Viral Vector Major Player Table 4. Protein Subunit Major Player Table 5. RNA Major Player Table 6. Others Major Player Table 7. Global Covid-19 Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Adults Major Player Table 9. Children Major Player Table 10. Covid-19 Vaccine Industry Trends Table 11. Covid-19 Vaccine Industry Drivers Table 12. Covid-19 Vaccine Industry Opportunities and Challenges Table 13. Covid-19 Vaccine Industry Restraints Table 14. Global Covid-19 Vaccine Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Covid-19 Vaccine Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Covid-19 Vaccine Market Share by Region (2021-2026) Table 17. Global Covid-19 Vaccine Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Covid-19 Vaccine Market Share by Region (2027-2032) Table 19. Global Covid-19 Vaccine Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Covid-19 Vaccine Revenue Market Share by Players (2021-2026) Table 21. Global Covid-19 Vaccine Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Covid-19 Vaccine Key Players Headquarters & Area Served Table 23. Global Covid-19 Vaccine Players, Product Type & Application Table 24. Global Covid-19 Vaccine Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Covid-19 Vaccine by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Covid-19 Vaccine Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Covid-19 Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Covid-19 Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Covid-19 Vaccine Revenue Market Share by Type (2021-2026) Table 31. Global Covid-19 Vaccine Revenue Market Share by Type (2027-2032) Table 32. Global Covid-19 Vaccine Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Covid-19 Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Covid-19 Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Covid-19 Vaccine Revenue Market Share by Application (2021-2026) Table 36. Global Covid-19 Vaccine Revenue Market Share by Application (2027-2032) Table 37. Moderna Company Information Table 38. Moderna Business Overview Table 39. Moderna Covid-19 Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Moderna Covid-19 Vaccine Product Portfolio Table 41. Moderna Recent Development Table 42. CanSino Biologicals Company Information Table 43. CanSino Biologicals Business Overview Table 44. CanSino Biologicals Covid-19 Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. CanSino Biologicals Covid-19 Vaccine Product Portfolio Table 46. CanSino Biologicals Recent Development Table 47. Inovio Pharmaceuticals Company Information Table 48. Inovio Pharmaceuticals Business Overview Table 49. Inovio Pharmaceuticals Covid-19 Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Inovio Pharmaceuticals Covid-19 Vaccine Product Portfolio Table 51. Inovio Pharmaceuticals Recent Development Table 52. Shenzhen Geno-Immune Medical Institute Company Information Table 53. Shenzhen Geno-Immune Medical Institute Business Overview Table 54. Shenzhen Geno-Immune Medical Institute Covid-19 Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Shenzhen Geno-Immune Medical Institute Covid-19 Vaccine Product Portfolio Table 56. Shenzhen Geno-Immune Medical Institute Recent Development Table 57. GlaxoSmithKine Company Information Table 58. GlaxoSmithKine Business Overview Table 59. GlaxoSmithKine Covid-19 Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. GlaxoSmithKine Covid-19 Vaccine Product Portfolio Table 61. GlaxoSmithKine Recent Development Table 62. Pfizer Company Information Table 63. Pfizer Business Overview Table 64. Pfizer Covid-19 Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Pfizer Covid-19 Vaccine Product Portfolio Table 66. Pfizer Recent Development Table 67. Johnson＆Johnson Company Information Table 68. Johnson＆Johnson Business Overview Table 69. Johnson＆Johnson Covid-19 Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Johnson＆Johnson Covid-19 Vaccine Product Portfolio Table 71. Johnson＆Johnson Recent Development Table 72. Heat Biologics Company Information Table 73. Heat Biologics Business Overview Table 74. Heat Biologics Covid-19 Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Heat Biologics Covid-19 Vaccine Product Portfolio Table 76. Heat Biologics Recent Development Table 77. Sanofi Company Information Table 78. Sanofi Business Overview Table 79. Sanofi Covid-19 Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Sanofi Covid-19 Vaccine Product Portfolio Table 81. Sanofi Recent Development Table 82. North America Covid-19 Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 83. North America Covid-19 Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 84. North America Covid-19 Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 85. North America Covid-19 Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 86. North America Covid-19 Vaccine Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 87. North America Covid-19 Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 88. North America Covid-19 Vaccine Revenue by Country (US$ Million) & (2027-2032) Table 89. Europe Covid-19 Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 90. Europe Covid-19 Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 91. Europe Covid-19 Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 92. Europe Covid-19 Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 93. Europe Covid-19 Vaccine Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 94. Europe Covid-19 Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 95. Europe Covid-19 Vaccine Revenue by Country (US$ Million) & (2027-2032) Table 96. China Covid-19 Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 97. China Covid-19 Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 98. China Covid-19 Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 99. China Covid-19 Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 100. Asia Covid-19 Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 101. Asia Covid-19 Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 102. Asia Covid-19 Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 103. Asia Covid-19 Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 104. Asia Covid-19 Vaccine Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 105. Asia Covid-19 Vaccine Revenue by Region (US$ Million) & (2021-2026) Table 106. Asia Covid-19 Vaccine Revenue by Region (US$ Million) & (2027-2032) Table 107. SAMEA Covid-19 Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 108. SAMEA Covid-19 Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 109. SAMEA Covid-19 Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 110. SAMEA Covid-19 Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 111. SAMEA Covid-19 Vaccine Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 112. SAMEA Covid-19 Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 113. SAMEA Covid-19 Vaccine Revenue by Country (US$ Million) & (2027-2032) Table 114. Research Programs/Design for This Report Table 115. Authors List of This Report Table 116. Secondary Sources Table 117. Primary Sources List of Figures Figure 1. Covid-19 Vaccine Image Figure 2. Global Covid-19 Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Covid-19 Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 4. DNA Image Figure 5. Non-replicating Viral Vector Image Figure 6. Protein Subunit Image Figure 7. RNA Image Figure 8. Others Image Figure 9. Global Covid-19 Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Covid-19 Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 11. Adults Image Figure 12. Children Image Figure 13. Global Covid-19 Vaccine Market Size (US$ Million) & (2021-2032) Figure 14. Global Covid-19 Vaccine Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Covid-19 Vaccine Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Covid-19 Vaccine Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Covid-19 Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Covid-19 Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Covid-19 Vaccine Revenue Market Share by Type (2021-2032) Figure 21. Global Covid-19 Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Covid-19 Vaccine Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Covid-19 Vaccine Revenue Market Share by Application (2021-2032) Figure 24. North America Covid-19 Vaccine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Covid-19 Vaccine Revenue Share by Type (2021-2032) Figure 26. North America Covid-19 Vaccine Revenue Share by Application (2021-2032) Figure 27. North America Covid-19 Vaccine Revenue Share by Country (2021-2032) Figure 28. United States Covid-19 Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Covid-19 Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Covid-19 Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Covid-19 Vaccine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Covid-19 Vaccine Revenue Share by Type (2021-2032) Figure 33. Europe Covid-19 Vaccine Revenue Share by Application (2021-2032) Figure 34. Europe Covid-19 Vaccine Revenue Share by Country (2021-2032) Figure 35. Germany Covid-19 Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Covid-19 Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Covid-19 Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Covid-19 Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Covid-19 Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Covid-19 Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Covid-19 Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Covid-19 Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Covid-19 Vaccine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Covid-19 Vaccine Revenue Share by Type (2021-2032) Figure 45. China Covid-19 Vaccine Revenue Share by Application (2021-2032) Figure 46. Asia Covid-19 Vaccine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Covid-19 Vaccine Revenue Share by Type (2021-2032) Figure 48. Asia Covid-19 Vaccine Revenue Share by Application (2021-2032) Figure 49. Asia Covid-19 Vaccine Revenue Share by Region (2021-2032) Figure 50. Japan Covid-19 Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Covid-19 Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Covid-19 Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Covid-19 Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Covid-19 Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Covid-19 Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Covid-19 Vaccine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Covid-19 Vaccine Revenue Share by Type (2021-2032) Figure 58. SAMEA Covid-19 Vaccine Revenue Share by Application (2021-2032) Figure 59. SAMEA Covid-19 Vaccine Revenue Share by Country (2021-2032) Figure 60. Brazil Covid-19 Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Covid-19 Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Covid-19 Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Covid-19 Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Covid-19 Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Covid-19 Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Covid-19 Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Covid-19 Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Covid-19 Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Covid-19 Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Covid-19 Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • DNA
  • Non-replicating Viral Vector
  • Protein Subunit
  • RNA
  • Others
Applications
  • Adults
  • Children
Companies covered
  • Moderna
  • CanSino Biologicals
  • Inovio Pharmaceuticals
  • Shenzhen Geno-Immune Medical Institute
  • GlaxoSmithKine
  • Pfizer
  • Johnson＆Johnson
  • Heat Biologics
  • Sanofi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Covid-19 Vaccine Market by Type
  3. 1.2.1 Global Covid-19 Vaccine Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 DNA
  5. 1.2.3 Non-replicating Viral Vector
  6. 1.2.4 Protein Subunit
  7. 1.2.5 RNA
  8. 1.2.6 Others
  9. 1.3 Covid-19 Vaccine Market by Application
  10. 1.3.1 Global Covid-19 Vaccine Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Adults
  12. 1.3.3 Children
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Covid-19 Vaccine Market Dynamics
  1. 2.1 Covid-19 Vaccine Industry Trends
  2. 2.2 Covid-19 Vaccine Industry Drivers
  3. 2.3 Covid-19 Vaccine Industry Opportunities and Challenges
  4. 2.4 Covid-19 Vaccine Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Covid-19 Vaccine Market Perspective (2021-2032)
  2. 3.2 Global Covid-19 Vaccine Growth Trends by Region
  3. 3.2.1 Global Covid-19 Vaccine Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Covid-19 Vaccine Market Size by Region (2021-2026)
  5. 3.2.3 Global Covid-19 Vaccine Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Covid-19 Vaccine Revenue by Players
  2. 4.1.1 Global Covid-19 Vaccine Revenue by Players (2021-2026)
  3. 4.1.2 Global Covid-19 Vaccine Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Covid-19 Vaccine Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Covid-19 Vaccine Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Covid-19 Vaccine Key Players Headquarters & Area Served
  7. 4.4 Global Covid-19 Vaccine Players, Product Type & Application
  8. 4.5 Global Covid-19 Vaccine Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Covid-19 Vaccine Market CR5 and HHI
  11. 4.6.3 2025 Covid-19 Vaccine Tier 1, Tier 2, and Tier 3
5 Covid-19 Vaccine Market Size by Type
  1. 5.1 Global Covid-19 Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Covid-19 Vaccine Revenue by Type (2021-2032)
  3. 5.3 Global Covid-19 Vaccine Revenue Market Share by Type (2021-2032)
6 Covid-19 Vaccine Market Size by Application
  1. 6.1 Global Covid-19 Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Covid-19 Vaccine Revenue by Application (2021-2032)
  3. 6.3 Global Covid-19 Vaccine Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Moderna
  2. 7.1.1 Moderna Company Information
  3. 7.1.2 Moderna Business Overview
  4. 7.1.3 Moderna Covid-19 Vaccine Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Moderna Covid-19 Vaccine Product Portfolio
  6. 7.1.5 Moderna Recent Developments
  7. 7.2 CanSino Biologicals
  8. 7.2.1 CanSino Biologicals Company Information
  9. 7.2.2 CanSino Biologicals Business Overview
  10. 7.2.3 CanSino Biologicals Covid-19 Vaccine Revenue and Gross Margin (2021-2026)
  11. 7.2.4 CanSino Biologicals Covid-19 Vaccine Product Portfolio
  12. 7.2.5 CanSino Biologicals Recent Developments
  13. 7.3 Inovio Pharmaceuticals
  14. 7.3.1 Inovio Pharmaceuticals Company Information
  15. 7.3.2 Inovio Pharmaceuticals Business Overview
  16. 7.3.3 Inovio Pharmaceuticals Covid-19 Vaccine Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Inovio Pharmaceuticals Covid-19 Vaccine Product Portfolio
  18. 7.3.5 Inovio Pharmaceuticals Recent Developments
  19. 7.4 Shenzhen Geno-Immune Medical Institute
  20. 7.4.1 Shenzhen Geno-Immune Medical Institute Company Information
  21. 7.4.2 Shenzhen Geno-Immune Medical Institute Business Overview
  22. 7.4.3 Shenzhen Geno-Immune Medical Institute Covid-19 Vaccine Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Shenzhen Geno-Immune Medical Institute Covid-19 Vaccine Product Portfolio
  24. 7.4.5 Shenzhen Geno-Immune Medical Institute Recent Developments
  25. 7.5 GlaxoSmithKine
  26. 7.5.1 GlaxoSmithKine Company Information
  27. 7.5.2 GlaxoSmithKine Business Overview
  28. 7.5.3 GlaxoSmithKine Covid-19 Vaccine Revenue and Gross Margin (2021-2026)
  29. 7.5.4 GlaxoSmithKine Covid-19 Vaccine Product Portfolio
  30. 7.5.5 GlaxoSmithKine Recent Developments
  31. 7.6 Pfizer
  32. 7.6.1 Pfizer Company Information
  33. 7.6.2 Pfizer Business Overview
  34. 7.6.3 Pfizer Covid-19 Vaccine Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Pfizer Covid-19 Vaccine Product Portfolio
  36. 7.6.5 Pfizer Recent Developments
  37. 7.7 Johnson＆Johnson
  38. 7.7.1 Johnson＆Johnson Company Information
  39. 7.7.2 Johnson＆Johnson Business Overview
  40. 7.7.3 Johnson＆Johnson Covid-19 Vaccine Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Johnson＆Johnson Covid-19 Vaccine Product Portfolio
  42. 7.7.5 Johnson＆Johnson Recent Developments
  43. 7.8 Heat Biologics
  44. 7.8.1 Heat Biologics Company Information
  45. 7.8.2 Heat Biologics Business Overview
  46. 7.8.3 Heat Biologics Covid-19 Vaccine Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Heat Biologics Covid-19 Vaccine Product Portfolio
  48. 7.8.5 Heat Biologics Recent Developments
  49. 7.9 Sanofi
  50. 7.9.1 Sanofi Company Information
  51. 7.9.2 Sanofi Business Overview
  52. 7.9.3 Sanofi Covid-19 Vaccine Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Sanofi Covid-19 Vaccine Product Portfolio
  54. 7.9.5 Sanofi Recent Developments
8 North America
  1. 8.1 North America Covid-19 Vaccine Revenue (2021-2032)
  2. 8.2 North America Covid-19 Vaccine Revenue by Type (2021-2032)
  3. 8.2.1 North America Covid-19 Vaccine Revenue by Type (2021-2026)
  4. 8.2.2 North America Covid-19 Vaccine Revenue by Type (2027-2032)
  5. 8.3 North America Covid-19 Vaccine Revenue Share by Type (2021-2032)
  6. 8.4 North America Covid-19 Vaccine Revenue by Application (2021-2032)
  7. 8.4.1 North America Covid-19 Vaccine Revenue by Application (2021-2026)
  8. 8.4.2 North America Covid-19 Vaccine Revenue by Application (2027-2032)
  9. 8.5 North America Covid-19 Vaccine Revenue Share by Application (2021-2032)
  10. 8.6 North America Covid-19 Vaccine Revenue by Country
  11. 8.6.1 North America Covid-19 Vaccine Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Covid-19 Vaccine Revenue by Country (2021-2026)
  13. 8.6.3 North America Covid-19 Vaccine Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Covid-19 Vaccine Revenue (2021-2032)
  2. 9.2 Europe Covid-19 Vaccine Revenue by Type (2021-2032)
  3. 9.2.1 Europe Covid-19 Vaccine Revenue by Type (2021-2026)
  4. 9.2.2 Europe Covid-19 Vaccine Revenue by Type (2027-2032)
  5. 9.3 Europe Covid-19 Vaccine Revenue Share by Type (2021-2032)
  6. 9.4 Europe Covid-19 Vaccine Revenue by Application (2021-2032)
  7. 9.4.1 Europe Covid-19 Vaccine Revenue by Application (2021-2026)
  8. 9.4.2 Europe Covid-19 Vaccine Revenue by Application (2027-2032)
  9. 9.5 Europe Covid-19 Vaccine Revenue Share by Application (2021-2032)
  10. 9.6 Europe Covid-19 Vaccine Revenue by Country
  11. 9.6.1 Europe Covid-19 Vaccine Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Covid-19 Vaccine Revenue by Country (2021-2026)
  13. 9.6.3 Europe Covid-19 Vaccine Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Covid-19 Vaccine Revenue (2021-2032)
  2. 10.2 China Covid-19 Vaccine Revenue by Type (2021-2032)
  3. 10.2.1 China Covid-19 Vaccine Revenue by Type (2021-2026)
  4. 10.2.2 China Covid-19 Vaccine Revenue by Type (2027-2032)
  5. 10.3 China Covid-19 Vaccine Revenue Share by Type (2021-2032)
  6. 10.4 China Covid-19 Vaccine Revenue by Application (2021-2032)
  7. 10.4.1 China Covid-19 Vaccine Revenue by Application (2021-2026)
  8. 10.4.2 China Covid-19 Vaccine Revenue by Application (2027-2032)
  9. 10.5 China Covid-19 Vaccine Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Covid-19 Vaccine Revenue (2021-2032)
  2. 11.2 Asia Covid-19 Vaccine Revenue by Type (2021-2032)
  3. 11.2.1 Asia Covid-19 Vaccine Revenue by Type (2021-2026)
  4. 11.2.2 Asia Covid-19 Vaccine Revenue by Type (2027-2032)
  5. 11.3 Asia Covid-19 Vaccine Revenue Share by Type (2021-2032)
  6. 11.4 Asia Covid-19 Vaccine Revenue by Application (2021-2032)
  7. 11.4.1 Asia Covid-19 Vaccine Revenue by Application (2021-2026)
  8. 11.4.2 Asia Covid-19 Vaccine Revenue by Application (2027-2032)
  9. 11.5 Asia Covid-19 Vaccine Revenue Share by Application (2021-2032)
  10. 11.6 Asia Covid-19 Vaccine Revenue by Country
  11. 11.6.1 Asia Covid-19 Vaccine Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Covid-19 Vaccine Revenue by Country (2021-2026)
  13. 11.6.3 Asia Covid-19 Vaccine Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Covid-19 Vaccine Revenue (2021-2032)
  2. 12.2 SAMEA Covid-19 Vaccine Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Covid-19 Vaccine Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Covid-19 Vaccine Revenue by Type (2027-2032)
  5. 12.3 SAMEA Covid-19 Vaccine Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Covid-19 Vaccine Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Covid-19 Vaccine Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Covid-19 Vaccine Revenue by Application (2027-2032)
  9. 12.5 SAMEA Covid-19 Vaccine Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Covid-19 Vaccine Revenue by Country
  11. 12.6.1 SAMEA Covid-19 Vaccine Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Covid-19 Vaccine Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Covid-19 Vaccine Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst